Advertisement

Für Sie Gelesen: Internationale Fachliteratur

  • R. S. Roß
Chapter

Zusammenfassung

Bislang ist es nicht möglich, das Hepatitis C-Virus (HCV) in In-vitro-Systemen zu kultivieren. Auch existiert kein Tiermodell, das sich zum Studium der viralen Replikation und zur experimentellen Evaluation von Strategien zur Behandlung der chronischen HCV-Infektion wirklich eignete. Unser Verständnis der molekularen Replikationsmechanismen des HCV wie der Pharmakodynamik einer Interferonbehandlung ist daher bis heute sehr begrenzt.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, Perelson AS (1998) Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-a-therapy. Science 282:103–107.PubMedCrossRefGoogle Scholar
  2. Zeuzem S, Lee JH, Franke A, Rüster B, Prummer O, Herrmann G, Roth WK (1998) Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa. Hepatology 27:1149–1156.PubMedCrossRefGoogle Scholar
  3. Fahrer H, Sauvain MJ, Zhioua E et al. (1998) Longterm survey (7 years) in a population at risk für Lyme borreliosis: What happens to the seropositive individials? Eur J Epid 14:117–123.CrossRefGoogle Scholar
  4. Arteage F, Golightly MG, Perez AG, Barrai M, Anda P, Garcia-Monco JC (1998) Disparity between serological reactivity to Borrelia burgdorferi and evidence of pats disease in a high risk group. Clin Inf Dis 27:1210–1213.CrossRefGoogle Scholar
  5. Silagy CA et al. (1998) Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A und B virus infections. Lancet 352:1877–1881.CrossRefGoogle Scholar
  6. Gubareva LV, Matrosovich MN, Brenner MK, Bethell RC, Webster RG(1998) Evidence for Zanamivir resistance in an immunocompromised child infected with influenza B virus. JID 178:1257–1262.PubMedCrossRefGoogle Scholar
  7. Laksy T, Terracciano GJ, Magder L, Koski CL, Ballesteros M, Nash, D, Clark S, Haber P, Stolley PD, Schonberger LB, Chen RT (1998) The Guillain-Barré Syndrome and the 1992–1993 and 1993–1994 influenza vaccines. New England Journal of Medicine 339; 1797:1845–1846.Google Scholar
  8. Kaul R, Jrabattoni D, Bwayo JJ, Arienti D, Zagliani A, Mwangi FM, Kariuki C, Ngugi EN, MacDonald KS, Ball TB, Clerici M, Plummer FA (1999) HIV-1-specific mucosal IgA in a cohort of HIV-1-resistant Kenyan sex workers. AIDS 13:23–29.PubMedCrossRefGoogle Scholar
  9. McChesney MB, Collins JR, Lu D, Lu X, Torten J, Ashley RL, CIoyd MW, Miller CJ (1998) Occult systemic infection and persistent simian immunodefiviency virs (SlV)-specific CD4 T-cell proliferative responses in rhesus macaques that were transiently viremic after intravaginal inoculation of SIV. J Vir 72:10029–10035.Google Scholar
  10. Zhu T, Corey L, Akridge R, Change Y, Feng F, Kim J, Alef C, McElroy A, Mullins J, McElrath J (1999) Evidence for HIV-1 latent infection in exposed seronegative individuals. 6th Conference on Retroviruses and Opportunistic Infections, Chicago 1999, Abstr.8.Google Scholar
  11. Armstrong GL, Conn LA, Pinner RW (1999) Trends in infectious disease mortality in the United States during the 20 th century. JAMA 281:61–66.PubMedCrossRefGoogle Scholar
  12. Coleman PJ, McQuillan GM, Moyer LA, Lambert SB, Margolis HS (1998) Incidence of Hepatitis B Virus infection in the United States, 1976–1994: estimates from the national health and nutrition examination surveys. JID 178:954–959.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1999

Authors and Affiliations

  • R. S. Roß
    • 1
  1. 1.Institut für Virologie, Nationales Referenzzentrum für Hepatitis CUniversitätsklinikum EssenEssenDeutschland

Personalised recommendations